The following papers were also read: The various problems connected with the diagnosis and management of a patient with phmochromocytoma should be approached under the following headings: think of it, confirm it, find it, and remove it.
Diagnosis
Many physicians have been looking for a patient with a phaeochromocytoma for years and have yet to find one, largely because they fail to think of the diagnosis. Patients presenting with 'attacks' are always a diagnostic challenge. Such attacks are more likely to be due to paroxysmal atrial tachycardia, migraine, anxiety state, dumping syndrome, hypoglycemia, epilepsy, hot flushes, &c., but a few will be due to phwochromocytoma. A typical attack usually begins with a sense of impending death, followed by pallor and palpita-tions, sometimes accompanied by angina, headache and profuse sweating, and terminating in profound weakness and exhaustion.
The prevalence of these tumours in the general population is not known. Estimates in the hypertensive population vary from 0.5 to 2%. Eleven thousand people die of hypertension annually in this country (Registrar-General's Statistical Review of England and Wales for 1969, HMSO, London); if 0.5% of these die of phaochromocytoma then about 50 people die unnecessarily every year, since most of these tumours escape detection.
The physician rarely has the opportunity of observing the attack. It is therefore useful to ask the patient to keep a diary of the frequency and nature of the attacks for a period which, provided they occur frequently, can be one or two weeks. The patient is then given phenoxybenzamine 5 mg twice daily (10 mg b.d. if hypertensive) for two weeks. If the attacks are reduced in frequency, the presence of a phwochromocytoma is possible. If the attacks continue, a ,-adrenergic blocking agent (e.g. propranolol 10 mg twice daily) is given for two weeks, as paroxysmal atrial tachycardia is a common alternative diagnosis. The use of this 'diary test' can save unnecessary admission to hospital for observation.
Laboratory Confirmation ofDiagnosis
Ideally all hypertensives should be screened for this tumour, as well as patients, normotensive or hypertensive, who have 'attacks'. A biological assay is used to. measure the excretion of adrenaline/noradrenaline in urine. In the last ten years 4453 urines have been screened and 66 tumours found (1.5%). These figures cannot be used to determine the prevalence of this tumour (except to give an upper limit), as they were derived partly from a selected population and partly from routine screening of hypertensives. All positive or equivocal samples are then analysed for their content of the stable metabolite 3-methoxy,4-hydroxy mandelic acid (VMA). Adrenaline and noradrenaline have the disadvantage of being excreted in microgram amounts (normal 24 h excretion <150 &g) and of being unstable both to temperature and to pH above 3.5. Care must therefore be taken in their preservation before analysis.
Immediately the diagnosis has been confirmed the patient should be placed on a-adrenergic blockade with phenoxybenzamine, to prevent sudden death from dysrhythmia or cerebral haemorrhage.
Localization ofTumour
If the predominant secretion of the tumour is adrenaline it is likely to be situated in the adrenal medulla, whereas if it is noradrenaline the tumour is likely to be extra-adrenal. The clinical manifestations of the two catecholamines vary, for instance adrenaline causes tachycardia, a wide pulse pressure and hyperglycemia whilst noradrenaline causes bradycardia and a narrow pulse pressure. Final localization is by radiology, with the patient under a-adrenergic blocade.
Removal o Tumour
Removal of the tumour can be hazardous. The mortality in patients with unsuspected tumours who are operated on for other complaints is 50 %, and in the days before routine preoperative preparation the operative mortality was 25 %. The main causes of death are: (1)hypertensive crises during handling of the tumour, which causes large amounts of catecholamine to be liberated into the circulation; (2) dysrhythmias leading to ventricular fibrillation; and (3) severe hypotension when the tumour is removed due to expansion of the circulatory bed and reduced circulating volume. To avoid these hazards the following programme of preoperative preparation has been evolved.
Day of operation minus 4 (D -4): Phenoxybenzamine 1 mg/kg in 250 ml 5 % glucose i.v.; crossmatch 10 pints of blood; keep patient in bed (postural hypotension). D -3: Phenoxybenzamine i.v. as above, or double dose if blood pressure not brought down to about 110/70 supine. D -2: Phenoxybenzamine i.v. as above or in dose sufficient to achieve blood pressure of 110/70 supine; propranolol 40 mg or practolol 400 mg by mouth to assess sensitivity. D -1: Phenoxybenzamine i.v.; practolol or propranolol only if heart rate exceeds 100. Day of operation: Phenoxybenzamine 50 mg i.v. at least two hours before operation begins; practolol by mouth if heart rate exceeds 100; intravenous propranolol during operation if arrhythmias develop; blood transfused from start of operation; hydrocortisone succinate available if adrenal gland has to be removed.
Breakdown ofCases and Results ofOperation
Thirty-eight cases of phwochromocytoma were seen in University College Hospital between 1954 and 1972, 24 in women and 14 in men. In 2 the diagnosis was unsuspected during life and made at post-mortem; in a further 2 the finding was accidental (1 provoked by operation for ureteric obstruction-survived; 1 provoked by deliverydied). The tumour was malignant in 4 cases (10%). The tumour was adrenal in 32 cases (84%), extra-adrenal in 4 cases (10%), multiple in adrenals in 3 (8%) and not localized in 2. In 29 cases (82 %) hypertension was persistent, and in 7 (18 %.) it was paroxysmal.
Removal ofpreviously localized benign tumour was performed in 27 cases (Mr B J Harries and Professor C G Clark). Of these 19 were normotensive after operation, 4 were still hypertensive, and 4 died, 3 from blood loss and one from postoperative infection (15 % operative mortality).
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